Trial | NCT00937664  Report issue

Title

Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine
A Phase I, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability & Pharmacokinetics of AZD7762 Administered as a Single Intravenous Agent and in Combination w/ Wkly Standard Dose Gemcitabine in Japanese Patients w/ Advanced Solid Malignancies

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Terminated

  • Study Participants

    24
The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD7762 when given with the approved drug gemcitabine based on the side effects experienced by patients that receive both drugs.
Study Started
Jul 31
2009
Primary Completion
Feb 28
2011
Anticipated
Study Completion
Feb 28
2011
Anticipated
Last Update
Feb 07
2011
Estimate

Drug AZD7762

solution, intravenous, weekly

Drug gemcitabine

intravenous, weekly

  • Other names: Gemzar

AZD7762 + gemcitabine Other

AZD7762 administered alone and in combination with gemcitabine

Criteria 

Inclusion Criteria:

Japanese patients with advanced solid tumors for which standard treatment does not exist or is no longer effective.
Must be suitable for treatment with gemcitabine
Relatively good overall health other than cancer

Exclusion Criteria:

Poor bone marrow function (not producing enough blood cells).
Poor liver or kidney function.
Serious heart conditions
No Results Posted